Next › Showing of 12
Recognizing Outstanding Achievement
June 5, 2017A NETRF-funded researcher earned the highest honor from the American Society of Clinical Oncology (ASCO) on June 3, 2017 as part of its Annual Meeting in Chicago. Carl June, MD, University of Pennsylvania, received the David A. Karnofsky Memorial Award for outstanding contributions to cancer research, diagnosis, and treatment. ... read more
Study shows rising rates of NET incidence, prevalence, and survival
May 19, 2017Why all these findings may be good news – A pivotal study of close to 65,000 patients over almost forty years shows significant changes in the incidence, prevalence, and overall survival of NETs. What are the implications of these major findings? Learn where and how we are making headway. ... read more
A one-of-a-kind symposium: reflection of the NETRF Director of Research
May 18, 2017The Neuroendocrine Tumor Research Foundation (NETRF) recently held its Annual Symposium at the beautiful Samberg Conference Center – MIT, in Cambridge, MA, overlooking the Charles River and the city of Boston. ... read more
New NET clinical trial launches in Texas
May 17, 2017Clinical researchers at MD Anderson Cancer Center are studying a new combination of therapies in neuroendocrine tumors (NETs). Researchers hope using an immunotherapy in combination with an anti-VEGF therapy will slow progression of the disease and extend survival. ... read more
2017 Annual Los Angeles Neuroendocrine Tumor Patient Education Conference
May 15, 2017Leaders in the field come together to offer the latest information in a daylong event on NET treatment, research, and survivorship. You will learn about emerging treatment approaches like PRRT and immunotherapy, plus advanced imaging and surgical techniques. You will also learn hands-on tips for improved nutrition and wellness. ... read more
Next › Showing of 12
